dRx Capital

Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

H1 is a New York-based healthcare platform founded in 2017 that serves as a connector for life sciences companies, hospitals, academic medical centers, and health systems. Its platform specializes in providing real-time data and analytics to facilitate informed decision-making throughout the therapeutic development process, from fundraising to product launch. By offering insights on healthcare professionals, clinical research, and industry experts, H1 enables organizations to benchmark their performance and access critical information that accelerates the discovery and development of therapies aimed at combating diseases. The company positions itself as a trusted source within the healthcare ecosystem, leveraging data to enhance collaboration and innovation across the industry.

Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, focuses on developing a digital therapeutic for myopia, or shortsightedness, a common visual condition affecting around one in three individuals globally. The company aims to create a clinically validated therapy to slow the progression of myopia in children and adolescents. Its innovative technology employs light stimulation targeting specific photosensitive cells in the retina, which modulates dopamine levels—a neurotransmitter that plays a crucial role in eye growth regulation. This digital therapeutic can be seamlessly integrated with smartphone use, making it an accessible solution for health professionals treating myopia. Dopavision is also supported by the German government through the "Industrie-in-Klinik" program, receiving €1.4 million over three years to advance its research and development efforts.

NuvoAir Medical, established in 2015 and headquartered in Stockholm, Sweden, specializes in a value-based specialty care platform for managing chronic heart and lung conditions. The company's core offering is a proactive, continuous virtual care model that combines personalized care, advanced monitoring technology, and analytics, delivered by a multidisciplinary team of healthcare professionals. NuvoAir collaborates with health plans and risk-bearing entities, employing flexible, value-based payment arrangements to reduce healthcare costs and improve patient outcomes.

Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.

Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

Aspen RxHealth is a Tampa, Florida-based company that provides an online platform designed to connect licensed pharmacists with patients requiring enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists to patients based on various social and clinical criteria, such as language and medication regimens. This platform enables health plans and providers to link their patients with a community of pharmacists who can deliver clinical services tailored to individual needs. The services offered include comprehensive medication reviews and targeted medication interventions, all aimed at optimizing communication and improving patient care.

H1 is a New York-based healthcare platform founded in 2017 that serves as a connector for life sciences companies, hospitals, academic medical centers, and health systems. Its platform specializes in providing real-time data and analytics to facilitate informed decision-making throughout the therapeutic development process, from fundraising to product launch. By offering insights on healthcare professionals, clinical research, and industry experts, H1 enables organizations to benchmark their performance and access critical information that accelerates the discovery and development of therapies aimed at combating diseases. The company positions itself as a trusted source within the healthcare ecosystem, leveraging data to enhance collaboration and innovation across the industry.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

H1 is a New York-based healthcare platform founded in 2017 that serves as a connector for life sciences companies, hospitals, academic medical centers, and health systems. Its platform specializes in providing real-time data and analytics to facilitate informed decision-making throughout the therapeutic development process, from fundraising to product launch. By offering insights on healthcare professionals, clinical research, and industry experts, H1 enables organizations to benchmark their performance and access critical information that accelerates the discovery and development of therapies aimed at combating diseases. The company positions itself as a trusted source within the healthcare ecosystem, leveraging data to enhance collaboration and innovation across the industry.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

RxVantage, Inc. is a healthcare technology company based in El Segundo, California, founded in 2007. It offers a web-based digital platform that connects healthcare providers with educational resources and experts from life science companies. The platform streamlines interactions between medical representatives and physicians' offices, enhancing patient outcomes and improving the efficiency of communication. By allowing practices to manage their interactions with pharmaceutical reps, RxVantage alleviates the burden of scheduling and coordination, thereby enabling healthcare staff to focus more on patient care. The platform includes features such as a dedicated scheduling calendar, a communication hub for efficient interactions, and resources for patient assistance and drug coupons. With over 11,000 representatives from 400 companies utilizing its services, RxVantage has facilitated more than 120,000 appointments with high-prescribing physicians, generating significant value for the pharmaceutical industry. The company aims to expand its reach and continue increasing the productivity of medical representatives, ultimately enhancing the educational resources available to healthcare providers.

Animantis, LLC is a software company based in San Diego, California, founded in 2014. It specializes in developing a cloud-based platform that leverages artificial intelligence for drug discovery and development. The platform employs computer vision and machine learning techniques to comprehensively characterize cellular functions, providing medical practitioners with valuable insights that enhance the prediction of drug efficacy and improve in vitro assay design. By maximizing the meaningful interpretation of cellular assays, Animantis aims to guide advancements in medicine and facilitate more effective therapeutic strategies.

Xealth Inc. operates a digital health prescribing platform that allows clinicians to integrate, prescribe, and monitor digital health tools directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, the platform facilitates patient engagement by enabling care teams to order appropriate digital health tools and programs, which can be sent to patients via email or patient portals. In addition to managing digital health prescriptions, the platform supports patient education and offers non-clinical services such as ride shares and food delivery. This comprehensive approach allows clinicians to monitor patient activity and engagement, ultimately enhancing the overall effectiveness of digital health initiatives within healthcare systems.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

SchoolCare is a digital health platform dedicated to enhancing pediatric healthcare in K-12 public schools. By providing free health technology, it assists school nurses in delivering effective care and ensuring student safety. The platform captures essential health information, including student medical charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. This connectivity allows for timely alerts about health events and supports the efficient operation of public school health programs. By addressing gaps in traditional care coordination, SchoolCare aims to improve health outcomes for children, ensuring that they receive consistent and comprehensive care throughout their school experience.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

Aktana Inc. is a technology company that specializes in AI-enabled marketing decision support software tailored for the life sciences sector. Founded in 2008 and headquartered in San Francisco, Aktana develops a platform that utilizes machine learning algorithms to assist sales and marketing teams in optimizing their engagement with healthcare professionals. Its key offerings include the Contextual Intelligence Engine, which allows executives to simulate various marketing strategies, and the Decision Support Engine, which analyzes diverse data sources to provide actionable insights directly within the representative’s existing CRM workflows. By focusing exclusively on the life sciences market, Aktana delivers data-driven suggestions that enhance multichannel marketing initiatives and improve overall campaign effectiveness. The company supports over 100 brands, including more than half of the top 20 pharmaceutical companies globally, helping them to maximize revenue and utilize data investments efficiently. Additionally, Aktana has offices in several international locations, including Tokyo, Shanghai, and Barcelona.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.